Combination of saroglitazar and gemfibrozil has a good safety profile and may be a novel therapy for type 2 diabetes mellitus and diabetic dyslipidemia.
Does the combination of saroglitazar and gemfibrozil have a good safety profile in patients with T2DM and diabetic dyslipidemia?
The combination of saroglitazar and gemfibrozil may represent a safe, novel therapeutic option for managing T2DM and diabetic dyslipidemia.
Tasa de eventos absoluta: 0% vs 0%
Hence, the combination of saroglitazar and gemfibrozil has shown a good safety profile and may represent a novel therapeutic agent that will fulfill the unmet needs in T2DM and diabetic dyslipidemia.
Uma Maheswari (Sun,) reported a other. Combination of saroglitazar and gemfibrozil has a good safety profile and may be a novel therapy for type 2 diabetes mellitus and diabetic dyslipidemia.